Novocure (NSDQ:NVCR) said today it inked a $15 million licensing agreement with Shanghai-based biopharma company Zai Lab to offer its Optune technology on the Chinese market and accelerate clinical trial enrollment in the region.
The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication.
Read the whole story on our sister site, Drug Delivery Business News
The post Novocure inks Chinese collaborative dev, commercialization deal with Zai Lab appeared first on MassDevice.
from MassDevice https://ift.tt/2xbo0Xo
Cap comentari:
Publica un comentari a l'entrada